Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI334 Phase I/II Study in Unresectable Locally Advanced or Metastatic Solid Tumors
CTR20233460Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI-334 in Nonhematologic neoplasms, sponsored by InnoCare Pharma. Started Nov 2023; status: completed.
02
Drugs
IBI-334
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233460.